Nobivac Piro


vaccine against babesiosis in dogs

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Nobivac Piro has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 30/05/2013

Authorisation details

Product details
Nobivac Piro
Agency product number
Active substance
soluble parasite antigen from Babesia canis and Babesia rossi
International non-proprietary name (INN) or common name
vaccine against babesiosis in dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

22/05/2013 Nobivac Piro - EMEA/V/C/000084 - R/0006


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for canidae

Therapeutic indication

For active immunisation of dogs of six months of age or older against Babesia canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume.

Onset of immunity: Three weeks after the basic vaccination course.

Duration of immunity: Six months after the last (re-)vaccination.

Assessment history

How useful was this page?

Add your rating